# Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers

> **NCT02171533** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** dabigatran
- **DRUG:** Verapamil
- **DRUG:** Verapamil ER

## Key facts

- **NCT ID:** NCT02171533
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171533, "Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02171533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*